Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study (Q39476907)

12 September 2017

title

Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study (English)

1 reference

12 September 2017

P Schwarzenberger

1

1 reference

12 September 2017

P Byrne

2

1 reference

12 September 2017

R Gaumer

3

1 reference

12 September 2017

J Norton

4

1 reference

12 September 2017

L Harrison

5

1 reference

12 September 2017

A Marrogi

6

1 reference

12 September 2017

J K Kolls

7

1 reference

12 September 2017

publication date

9 September 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

18

1 reference

12 September 2017

issue

12

1 reference

12 September 2017

page(s)

906-912

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2011.60

12 September 2017

exact match

0 references

cites work

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

Activation by thymidine kinase and potent antiherpetic activity of 2′-nor-2′-deoxyguanosine (2′NDG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

Gene therapy for mesothelioma and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II–III malignant pleural mesothelioma☆

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

Use of suicide genes in gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

7 January 2021

Immune system in suicide-gene therapy

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

7 January 2021

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

7 January 2021

Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274)

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

7 January 2021

Gene therapy for malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

7 January 2021

Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2011.60

7 January 2021

Identifiers

DOI

10.1038/CGT.2011.60

1 reference

Dimensions Publication ID

12 September 2017

1021711082

0 references

Fatcat ID

release_cdomeqex3zbnjgycupejwvw4e4

0 references

1 reference